Javitt Daniel C.'s Form 4 filing
NRX Pharmaceuticals, Inc. (NRXP) · filed Jun 7, 2022
- Accession no.
- 0000880984-22-000007
- Filed
- Jun 7, 2022
- Trade date
- Jun 3-7, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $304.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Javitt Daniel C.CIK 0001864534 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 | Common Stock | SSaleDisposed | −243,596 | $0.70 | −$170,517.2 | 12,859,080 | Indirect | |
| Jun 6, 2022 | Common Stock | SSaleDisposed | −115,657 | $0.67 | −$77,490.19 | 12,743,423 | Indirect | |
| Jun 7, 2022 | Common Stock | SSaleDisposed | −86,459 | $0.65 | −$56,198.35 | 12,656,964 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.